12/17
04:18 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16
05:49 pm
jazz
Jazz to search for new chief as CEO plans retirement [Yahoo! Finance]
Low
Report
Jazz to search for new chief as CEO plans retirement [Yahoo! Finance]
12/16
04:13 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan [Yahoo! Finance]
12/16
04:05 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan
12/16
04:05 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan
12/12
01:07 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.
12/12
09:07 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $175.00 price target on the stock, up previously from $140.00.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $175.00 price target on the stock, up previously from $140.00.
12/12
08:26 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
12/10
10:20 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $179.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $179.00 price target on the stock.
12/6
04:05 pm
jazz
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Low
Report
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
12/5
07:48 am
jazz
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®) [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®) [Yahoo! Finance]
12/5
07:45 am
jazz
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Low
Report
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
12/4
04:19 pm
jazz
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 [Yahoo! Finance]
12/4
04:15 pm
jazz
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
Low
Report
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
12/4
04:15 pm
jazz
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
Low
Report
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
12/3
07:49 am
jazz
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
Low
Report
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
11/29
12:04 pm
jazz
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet [Yahoo! Finance]
11/28
05:55 am
jazz
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy? [Yahoo! Finance]
Low
Report
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy? [Yahoo! Finance]
11/25
05:53 am
jazz
US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer [Yahoo! Finance]
Low
Report
US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer [Yahoo! Finance]
11/22
03:17 pm
jazz
FDA Roundup: November 22, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: November 22, 2024 [Yahoo! Finance]
11/22
08:13 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
11/21
01:30 pm
jazz
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]
Low
Report
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]
11/21
12:57 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.